Therapeutic Protein Drug–Drug Interactions: Navigating the Knowledge Gaps–Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop
Open Access
- 21 June 2013
- journal article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 15 (4), 933-940
- https://doi.org/10.1208/s12248-013-9495-1
Abstract
The investigation of therapeutic protein drug–drug interactions has proven to be challenging. In May 2012, a roundtable was held at the American Association of Pharmaceutical Scientists National Biotechnology Conference to discuss the challenges of preclinical assessment and in vitro to in vivo extrapolation of these interactions. Several weeks later, a 2-day workshop co-sponsored by the U.S. Food and Drug Administration and the International Consortium for Innovation and Quality in Pharmaceutical Development was held to facilitate better understanding of the current science, investigative approaches and knowledge gaps in this field. Both meetings focused primarily on drug interactions involving therapeutic proteins that are pro-inflammatory cytokines or cytokine modulators. In this meeting synopsis, we provide highlights from both meetings and summarize observations and recommendations that were developed to reflect the current state of the art thinking, including a four-step risk assessment that could be used to determine the need (or not) for a dedicated clinical pharmacokinetic interaction study.Keywords
This publication has 39 references indexed in Scilit:
- Pharmacokinetic mAb–mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor XenograftsThe AAPS Journal, 2012
- AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical DevelopmentThe AAPS Journal, 2011
- Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte CulturePublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2011
- Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liverGenome Research, 2010
- Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- Applications of population pharmacokinetics in current drug labellingJournal of Clinical Pharmacy & Therapeutics, 2007
- KUPFFER CELL-MEDIATED IL-2 SUPPRESSION OF CYP3A ACTIVITY IN HUMAN HEPATOCYTESDrug Metabolism and Disposition, 2004
- Cytochrome P450 3A4 activity after surgical stressCritical Care Medicine, 2003
- The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytesGastroenterology, 1995
- Estimation of population characteristics of pharmacokinetic parameters from routine clinical dataJournal of Pharmacokinetics and Biopharmaceutics, 1977